Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome
Clinical trial NCT04540120 · TERMINATED
Trial details
- NCT number
- NCT04540120
- Sponsor
- Olatec Therapeutics, Inc.
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-09-24
- Primary completion
- 2022-07-28
- Enrollment
- 49
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.